TRVI insider trading
NasdaqGM HealthcareTrevi Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Company website: www.trevitherapeutics.com
TRVI insider activity at a glance
FilingIQ tracks 191 insider transactions for TRVI in filings since May 13, 2019. The most recent transaction is dated Sep 15, 2026.
Across the full history, 60 open-market purchases
and 48 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TRVI insider trades is 53.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TRVI Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TRVI?
- FilingIQ tracks 191 Form 4 insider transactions for TRVI (Trevi Therapeutics, Inc.), covering filings from May 13, 2019 onwards. 6 of those are dated within the last 90 days.
- Are TRVI insiders net buyers or net sellers?
- Across the full Form 4 history for TRVI, 60 transactions (31%) were open-market purchases and 48 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TRVI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TRVI in?
- Trevi Therapeutics, Inc. (TRVI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.36B.
Methodology & sources
Every TRVI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.